Expanded Indications for GLP-1 Receptor Agonists The 2025 American Diabetes Association (ADA) Standards of Care have broadened the use of GLP-1 receptor agonists beyond glycemic control
Brain activation in response to low-calorie food pictures: an explorative analysis of a randomized trial with dapagliflozin and exenatide
Harmful alcohol consumption is estimated to contribute to over 5% of global deaths and is the leading cause of preventable mortality.74 Additionally, approximately 5 million people worldwide are estimated to have cocaine use disorder145 and approximately 58 million individuals use opioids, including synthetic variants.146 The pathophysiology of addiction has been extensively investigated, revealing drug-induced dysregulation of multiple neural circuits and neurochemical systems, including dopamine, opioid peptides, corticotropin-releasing factor, dynorphin, glutamate, and gamma-aminobutyric acid (GABA)
However, clinical trials such as STEP-4 demonstrate that weight regain typically occurs after discontinuation of therapy
On the other hand, the clinical trials on semaglutide (Wegovy) for weight loss have been clear: On average, people taking that medication lose 15% of their body weight over 68 weeks compared to 2.4% of body weight in those taking a placebo
